New and incremental FDA black box warnings from 2008 to 2015

ABSTRACT Background: The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often warns of serious risks. The objective of this study was to comprehensively characterize BBWs issued for drugs after FDA approval. Methods: We identified all post-marketing BBWs from January 2008 through June 2015 listed on FDA’s MedWatch and Drug Safety Communications websites. We used each drug’s prescribing information to classify its BBW as new, major update to a preexisting BBW, or minor update. We then characterized these BBWs with respect to pre-specified BBW-specific and drug-specific features. Results: There were 111 BBWs issued to drugs on the US market, of which 29% (n = 32) were new BBWs, 32% (n = 35) were major updates, and 40% (n = 44) were minor updates. New BBWs and major updates were most commonly issued for death (51%) and cardiovascular risk (27%). The new BBWs and major updates impacted 200 drug formulations over the study period, of which 64% were expected to be used chronically and 58% had available alternatives without a BBW. Conclusions: New BBWs and incremental updates to existing BBWs are frequently added to drug labels after regulatory approval.

[1]  J. Ross,et al.  Association between FDA black box warnings and Medicare formulary coverage changes. , 2017, The American journal of managed care.

[2]  Harlan M. Krumholz,et al.  Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.

[3]  G. D. Dal Pan,et al.  Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals , 2017, Drug Safety.

[4]  H. Krumholz,et al.  Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals , 2016, Trials.

[5]  R. Vleugels,et al.  The Value of the Black Box Warning in Dermatology. , 2015, Journal of drugs in dermatology : JDD.

[6]  D. Lubeck,et al.  Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease , 2015, Drugs in context.

[7]  C. Blanchette,et al.  Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function , 2015, Drugs in context.

[8]  Jaekyu Shin,et al.  Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012. , 2014, JAMA internal medicine.

[9]  Steffie Woolhandler,et al.  Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. , 2014, Health affairs.

[10]  Harlan M. Krumholz,et al.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.

[11]  R. DiSantostefano,et al.  An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005–2011 , 2013, The Journal of asthma : official journal of the Association for the Care of Asthma.

[12]  G. D. Dal Pan,et al.  Evaluation of FDA safety‐related drug label changes in 2010 , 2013, Pharmacoepidemiology and drug safety.

[13]  E. Dorsey,et al.  Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review , 2012, Medical care.

[14]  Valeri Craigle.  MedWatch–The FDA Safety Information and Adverse Event-Reporting Program , 2007, Red Book (2012).

[15]  Robert L Davis,et al.  FDA drug prescribing warnings: is the black box half empty or half full? , 2006, Pharmacoepidemiology and drug safety.

[16]  Nidhi R. Shah,et al.  Adherence to black box warnings for prescription medications in outpatients. , 2006, Archives of internal medicine.

[17]  M. Fotis.  Risk Evaluation and Mitigation Strategies (REMS) , 2012 .